



CEOcast, Inc.
Dan Schustack
Investor Relations
Tel: (212) 732-4300
Email: DSchustack@ceocast.com

ImmunoCellular Therapeutics' Chief Executive Officer to Present at Prestigious Cancer Stem Cell Conference

LOS ANGELES, CA – December 8, 2010 – ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, announced today that Manish Singh Ph.D., the company's President and Chief Executive Officer, will present at the World Cancer Stem Cell Summit at the Boston Park Plaza Hotel & Towers in Boston, MA. on Thursday, December 9th at 2:05 p.m.

The World CSC Summit focuses on overcoming the challenges faced in utilizing cancer stem cell therapies, exploring the very latest lines of research and the move into clinical trials. The event features innovative case studies and cutting-edge practical insights, bringing together thought leaders from all areas involved in cancer stem cell study. For more information about the World Cancer Stem Cell Conference, please visit www.csc-summit.com.

About ImmunoCellular Therapeutics, Ltd.

IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently completed a Phase I trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma. The Company is planning to initiate a multicenter Phase II study in late 2010. The Company's "off the shelf" therapeutic vaccine product candidate (ICT-121) targeting cancer stem cells for multiple cancer indications is targeted by IMUC to enter clinical trials during the first half of 2011. To learn more about IMUC, please visit www.imuc.com.

Forward-Looking Statements

This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including without limitation the need for substantial additional capital to fund development of product candidates beyond their initial clinical or pre-clinical stages; the risk that the safety and efficacy results obtained in the Phase I trial for ICT-107 will not be confirmed in subsequent trials; the risk that IMUC will not be able to secure a partner company for development or commercialization of ICT-107; the need to satisfy performance milestones to maintain the vaccine technology licenses with Cedars-Sinai; the risks associated with obtaining FDA clearance to commence clinical trials of the cancer stem cell vaccine on a timely basis or at all, including the need to successfully complete required animal toxicity studies; the risks associated with adhering to projected preclinical or clinical timelines and the uncertainties of outcomes of development work for product candidates, including those based on destroying cancer stem cells as a potentially safe and effective treatment for various cancers; and the risk of obtaining patent coverage for the dendritic cell-based vaccine or cancer stem cell vaccine or that any patents covering those vaccines will provide commercially significant protection for these technologies. Additional risks and uncertainties are described in IMUC's most recently filed SEC documents, such as its most recent annual report on Form 10-K, all quarterly reports on Form 10-Q and any current reports on Form 8-K. IMUC undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.